Reaktionsgleichung
[C:1]([C:5]1[CH:9]=[C:8]([NH:10][C:11](=[O:13])[O-])[N:7]([C:14]2[CH:19]=[CH:18][CH:17]=[CH:16][CH:15]=2)[N:6]=1)([CH3:4])([CH3:3])[CH3:2].[Cl:20][C:21]1[CH:27]=[CH:26][C:25]([O:28][C:29]2[C:38]3[C:33](=[CH:34][C:35]([O:41][CH3:42])=[C:36]([O:39][CH3:40])[CH:37]=3)[N:32]=[CH:31][N:30]=2)=[CH:24][C:22]=1[NH2:23]>>[C:1]([C:5]1[CH:9]=[C:8]([NH:10][C:11]([NH:23][C:22]2[CH:24]=[C:25]([O:28][C:29]3[C:38]4[C:33](=[CH:34][C:35]([O:41][CH3:42])=[C:36]([O:39][CH3:40])[CH:37]=4)[N:32]=[CH:31][N:30]=3)[CH:26]=[CH:27][C:21]=2[Cl:20])=[O:13])[N:7]([C:14]2[CH:19]=[CH:18][CH:17]=[CH:16][CH:15]=2)[N:6]=1)([CH3:2])([CH3:3])[CH3:4]Komponenten
3
Versuchsvorschrift
The title compound was prepared from 3-tert-butyl-1-phenyl-1H-pyrazol-5-ylcarbamate (100 mg, 0.30 mmol) and 2-chloro-5-(6,7-dimethoxyquinazolin-4-yloxy)aniline (100 mg, 0.30 mmol) using the procedure in Example 115C to give 1-(3-tert-butyl-1-phenyl-1H-pyrazol-5-yl)-3-(2-chloro-5-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)urea (34 mg, 0.06 mmol, 20%). 1H NMR (300 MHz, DMSO-d6) δ 9.33 (s, 1H), 8.81 (s, 1H), 8.56 (s, 1H), 8.11 (s, 1H), 7.57-7.52 (m, 6H), 7.44-7.40 (m, 2H), 7.01 (d, 1H), 6.36 (s, 1H), 3.98 (s, 6H), 1.24 (s, 9H); LC-MS (ESI) m/z 573 (M)+.
Quellen und Nachweise
- ORD-Eintrag
- ord-e16e4c8418a6493ea892920755771586
- Quelldatensatz
- uspto-grants-2015_03
- Patentnummer
- US08969587B2
Verknüpfte Notizen
Wird geladen…